National Institute of Health (NIH) has started the local manufacturing of CanSinoBIO’s COVID-19 vaccine after importing the raw material from China.
According to a statement by NIH, the raw material imported from the neighboring country is sufficient to produce 120,000 doses, which will be available for use by the end of May.
NIH researchers are working along with Chinese scientists for the manufacturing of CanSinoBIO’s COVID-19 vaccine.
Last month, NIH had announced to start local production of CanSinoBIO’s vaccine in May.
About CanSinoBIO’s Vaccine
Known as Ad5-nCoV, CanSinoBIO developed the Coronavirus vaccine in collaboration with the Beijing Institute of Biotechnology and tested it in large-scale phase-III clinical trials that were held in five countries, including Pakistan, in which more than 40,000 volunteers participated.
Results of trials were published in February this year which confirmed that the CanSinoBIO vaccine was 65% effective at preventing symptomatic cases and 91% effective at preventing severe infection.
As for the Pakistani subset, the vaccine offered 75% protection against symptomatic cases and 100% protection against severe infection.
No serious safety concerns and side-effects of the CanSinoBIO vaccine were reported during the multination clinical trials as well.
Earlier this year in February, the Drug Regulatory Authority of Pakistan (DRAP) had granted Emergency Use Authorization (EUA) to CanSinoBIO’s COVID-19 vaccine.